Dr Lal PathLabs Q4 net profit down by 31 per cent to Rs 32.6 cr

Published On 2020-05-19 09:07 GMT   |   Update On 2020-05-19 11:53 GMT

New Delhi: Diagnostics chain Dr Lal PathLabs on Monday reported a 31.2 per cent decline in its consolidated net profit to Rs 32.6 crore for the quarter ended on March 31, 2020.The company had posted a net profit of Rs 47.4 crore for the corresponding period of previous fiscal, Dr Lal PathLabs said in a BSE filing.Consolidated revenue from operations stood at Rs 301.7 crore for the quarter...

Login or Register to read the full article

New Delhi: Diagnostics chain Dr Lal PathLabs on Monday reported a 31.2 per cent decline in its consolidated net profit to Rs 32.6 crore for the quarter ended on March 31, 2020.

The company had posted a net profit of Rs 47.4 crore for the corresponding period of previous fiscal, Dr Lal PathLabs said in a BSE filing.

Consolidated revenue from operations stood at Rs 301.7 crore for the quarter under consideration as against Rs 301.1 crore in the same period year ago, it added.

"We are in unprecedented and difficult times. These times are not only impacting the current financial year but impacted Q4FY20 results as well not just for Dr Lal Pathlabs, but for the entire nation and the economy. The business was impacted adversely, with volumes getting hit," Dr Lal PathLabs Executive Chairman Arvind Lal said.

For the full year 2019-20, the company posted a net profit of Rs 227.6 crore. It was Rs 200.5 crore in the year-ago period, the filing said.

Consolidated revenue from operations stood at Rs 1,330.4 crore for the fiscal ended March this year. It was Rs 1,203.4 crore in 2018-19.

Shares of Dr Lal PathLabs closed at Rs 1,583.35 per scrip on the BSE, down 0.78 per cent over the previous close.

Read also: Cipla board nod to Rs 3000 crore fundraising proposal

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News